

=> b reg

FILE 'REGISTRY' ENTERED AT 08:56:50 ON 10 DEC 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 9 DEC 2003 HIGHEST RN 625365-36-8  
 DICTIONARY FILE UPDATES: 9 DEC 2003 HIGHEST RN 625365-36-8

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003


Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que stat 17

L1 STR



VAR G1=O/S/N  
 REP G2=(0-9) CH2  
 REP G3=(0-10) CH2  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
 L2 SCR 1237  
 L3 SCR 1236 AND 1297  
 L4 SCR 1236 AND 1332  
 L5 SCR 1235 AND 1298  
 L6 SCR 1235 AND 1332  
 L7 35 SEA FILE=REGISTRY SSS FUL L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

100.0% PROCESSED 476996 ITERATIONS  
 SEARCH TIME: 00.00.38

35 ANSWERS

Russel 09/720,045

=> b cap

FILE 'CAPLUS' ENTERED AT 08:57:00 ON 10 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2003 VOL 139 ISS 24  
FILE LAST UPDATED: 9 Dec 2003 (20031209/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos 18

L1	STR
L2	SCR 1237
L3	SCR 1236 AND 1297
L4	SCR 1236 AND 1332
L5	SCR 1235 AND 1298
L6	SCR 1235 AND 1332
L7	35 SEA FILE=REGISTRY SSS FUL L1 AND (L2 OR L3 OR L4 OR L5 OR L6)
L8	3 SEA FILE=CAPLUS ABB=ON PLU=ON L7

=> b uspatfull;d que nos 19

FILE 'USPATFULL' ENTERED AT 08:57:22 ON 10 DEC 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Dec 2003 (20031209/PD)  
FILE LAST UPDATED: 9 Dec 2003 (20031209/ED)  
HIGHEST GRANTED PATENT NUMBER: US6662368  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003226186  
CA INDEXING IS CURRENT THROUGH 9 Dec 2003 (20031209/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Dec 2003 (20031209/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2003

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<
>>> USPATFULL. A USPATFULL record contains not only the original	<<<
>>> published document but also a list of any subsequent	<<<
>>> publications. The publication number, patent kind code, and	<<<
>>> publication date for all the US publications for an invention	<<<
>>> are displayed in the PI (Patent Information) field of USPATFULL	<<<

```
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1 STR
L2 SCR 1237
L3 SCR 1236 AND 1297
L4 SCR 1236 AND 1332
L5 SCR 1235 AND 1298
L6 SCR 1235 AND 1332
L7 35 SEA FILE=REGISTRY SSS FUL L1 AND (L2 OR L3 OR L4 OR L5 OR L6)
L9 1 SEA FILE=USPATFULL ABB=ON PLU=ON L7
```

```
=> dup rem 18,19
FILE 'CAPLUS' ENTERED AT 08:57:41 ON 10 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'USPATFULL' ENTERED AT 08:57:41 ON 10 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L8
PROCESSING COMPLETED FOR L9
L12 4 DUP REM L8 L9 (0 DUPLICATES REMOVED)
```

```
=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y
```

```
L12 ANSWER 1 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2003:289093 USPATFULL
TITLE: Acyl pseudodipeptides which carry a functionalised
auxiliary arm
INVENTOR(S): Bauer, Jacques, Saint Prex, SWITZERLAND
Martin, Olivier Richard, Orleans, FRANCE
Rodriguez, Sylvain, Gland, SWITZERLAND
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203852	A1	20031030
APPLICATION INFO.:	US 2002-169053	A1	20020828 (10)
	WO 2000-FR3650		20001221

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1999-IB2038	19991222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Bierman Muserlian and Lucas, 600 Third Avenue, New	

York, NY, 10015  
 NUMBER OF CLAIMS: 41  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 86 Drawing Page(s)  
 LINE COUNT: 5631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state.

Compounds of the present invention have immunomodulating properties like adjuvants, In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targetting thereof. Accordingly, compounds of the invention find use in human and veterinary medicine both as immunogens and diagnostic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 346669-87-2P

(preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer)

RN 346669-87-2 USPATFULL

CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 346669-86-1P 346669-94-1P 346670-02-8P

346670-10-8P 346670-11-9P 346670-13-1P

346670-14-2P 346670-15-3P 346670-18-6P

346670-19-7P 346670-20-0P 346670-22-2P

346670-25-5P 346670-26-6P 346670-27-7P

346670-28-8P


(preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer)

RN 346669-86-1 USPATFULL


CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6,7-dihydroxy-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346669-94-1 USPATFULL

CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6-amino-1-oxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346670-02-8 USPATFULL

CN Dodecanoic acid, (1R)-1-[2-[[[(1S)-1-[[[(4R)-5-[(6-hydroxy-1-oxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346670-10-8 USPATFULL


CN Dodecanoic acid, (1R)-1-[2-[[[(1R)-1-[(carboxymethoxy)methyl]-2-[[[(4R)-5-[(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 346670-11-9 USPATFULL


CN Tetradecanoic acid, (1R)-1-[2-[[[(1S)-2-[[[(4R)-5-[(7-amino-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-1-[[[(carboxymethyl)thio]methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 346670-13-1 USPATFULL


CN Propanedioic acid, [[(2R)-3-[[[(4R)-5-[(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-3-oxo-2-[[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]propoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 346670-14-2 USPATFULL


CN Dodecanoic acid, (1R,11R)-22-bromo-11-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-3,6,14,21-tetraoxo-5-[2-(phosphonoxy)ethyl]-1-undecyl-13-oxa-4,7,20-triazadocos-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346670-15-3 USPATFULL  
 CN Dodecanoic acid, (1R,5R)-5-[[[(1,6-dioxohexyl)oxy]methyl]-15,15-dihydroxy-11-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-15-oxido-3,10-dioxo-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346670-18-6 USPATFULL  
 CN Glycine, N-[(9R,19R)-9-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-6,14,17,21-tetraoxo-15-[2-(phosphonooxy)ethyl]-19-undecyl-7,20-dioxo-13,16-diazadotriacont-1-yl]-L-phenylalanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




RN 346670-19-7 USPATFULL

CN Dodecanoic acid, 1-[2-[[1-[[[5-[(1,6-dioxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)




RN 346670-20-0 USPATFULL

CN Dodecanoic acid, 1-[2-[[1-[[[5-[(6-amino-1-oxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)



RN 346670-22-2 USPATFULL


CN Dodecanoic acid, 1-[2-[[1-[[[5-[(6-hydroxy-1-oxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)



RN 346670-25-5 USPATFULL

CN    Tetradecanoic acid, 1-[2-[[2-[[5-[(7-amino-1-oxoheptyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]-1-[[ (carboxymethyl)thio]methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI)    (CA INDEX NAME)


PAGE 1-A



$$-(\text{CH}_2)_{10}-\text{Me}$$

Propanedioic acid, [[3-[[5-[(1,6-dioxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]-3-oxo-2-[[1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]propoxy)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

$$-(\text{CH}_2)_{10}-\text{Me}$$


KN	340670-27-7	9CI	CA INDEX NAME
CN	Dodecanoic acid, 22-bromo-11-[(3-hydroxy-1-oxotetradecyl)amino]-3,6,14,21-tetraoxo-5-[2-(phosphonooxy)ethyl]-1-undecyl-13-oxa-4,7,20-triazadocos-1-yl ester (9CI) (CA INDEX NAME)		



RN 346670-28-8 USPATFULL

CN Dodecanoic acid, 5-[[[(1,6-dioxohexyl)oxy]methyl]-15,15-dihydroxy-11-[(3-hydroxy-1-oxotetradecyl)amino]-15-oxido-3,10-dioxo-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— (CH<sub>2</sub>)<sub>10</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me


IT 253587-01-8P 346669-83-8P 346669-84-9P  
 346669-85-0P 346669-92-9P 346669-93-0P  
 346670-00-6P 346670-01-7P

(preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer)

RN 253587-01-8 USPATFULL

CN Dodecanoic acid, (1R,11R,15R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-11-(hydroxymethyl)-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346669-83-8 USPATFULL


CN Dodecanoic acid, (1R,11R,15R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-3,6,13-trioxo-11-[[[(1-oxo-6-heptenyl)oxy]methyl]-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346669-84-9 USPATFULL  
 CN Dodecanoic acid, (1R,11R,15R)-11-[[[(6,7-dihydroxy-1-oxoheptyl)oxy]methyl]-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346669-85-0 USPATFULL  
 CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6,7-dihydroxy-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-[(diphenoxyphosphinyl)oxy]propyl]amino]-2-oxoethyl]dodecyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346669-92-9 USPATFULL  
 CN 9,22-Dioxa-2,15,18-triazatetratriacontanoic acid, 17-[2-[(diphenoxyphosphinyl)oxy]ethyl]-8,16,19,23-tetraoxo-11-[[[(3R)-1-oxo-3-(phenylmethoxy)tetradecyl]amino]-21-undecyl-, phenylmethyl ester, (11R,21R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346669-93-0 USPATFULL  
 CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6-amino-1-oxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-[(diphenoxyphosphinyl)oxy]propyl]amino]-2-oxoethyl]dodecyl ester (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 346670-00-6 USPATFULL

CN Dodecanoic acid, (1R,5S,11R,15R)-5-(2-hydroxyethyl)-3,6,13-trioxo-17-phenyl-11-[[ (phenylmethoxy)methoxy]methyl]-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346670-01-7 USPATFULL

CN Dodecanoic acid, (1R,5S,11R,15R)-5-[2-[[bis (phenylmethoxy)phosphinyl]oxy]ethyl]-11-(hydroxymethyl)-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:195779 CAPLUS

DOCUMENT NUMBER: 139:173430

TITLE: OM197-MP-AC induces the maturation of human dendritic cells and promotes a primary T cell response

AUTHOR(S): Byl, B.; Libin, M.; Bauer, J.; Martin, O. R.; De Wit, D.; Davies, G.; Goldman, M.; Willems, F.

CORPORATE SOURCE: Laboratoire d'Immunologie Experimentale, Universite Libre de Bruxelles, Brussels, Belg.

SOURCE: International Immunopharmacology (2003), 3(3), 417-425  
CODEN: IINMBA; ISSN: 1567-5769

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dendritic cell (DC) maturation is critical for the induction of



antigen-specific T lymphocyte responses and may be essential for the development of human vaccines relying on T cell immunity. We investigated the effects on human DC of OM-197, a synthetic pseudodipeptide derived from amino acids, linked to three fatty acid chains and devoid of endotoxin properties. OM-197 upregulated the expression of HLA-DR, CD80, CD86, CD83, CD40 and CD54 at the surface of myeloid DC naturally present in blood as well as of DC generated in vitro from monocytes using IL-4 and GM-CSF. OM-197 also induced the release of IL-12 and TNF- $\alpha$  from DC. Finally, DC incubated with OM-197 after pulsing with hepatitis B surface antigen (HBs Ag) induced in vitro expansion of IFN- $\gamma$ -secreting HBs Ag-specific CD4<sup>+</sup> T lymphocytes from naive individuals. Taken together, these data identify OM-197 as a potential vaccine adjuvant for the induction of Th1-type responses.

IT 579489-31-9


RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(OM197-MP-AC induces the maturation of human dendritic cells and promotes a primary T cell response)

RN 579489-31-9 CAPLUS

CN Dodecanoic acid, (1R)-1-[2-[[[(1S)-1-[[[(4R)-5-[(6-amino-1-oxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:472655 CAPLUS

DOCUMENT NUMBER: 135:77104

TITLE: Preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer

INVENTOR(S): Bauer, Jacques; Martin, Olivier Richard; Rodriguez, Sylvain

PATENT ASSIGNEE(S): OM Pharma, Switz.

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046127	A1	20010628	WO 1999-IB2038	19991222

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000015814 A5 20010703 AU 2000-15814 19991222  
 WO 2001046126 A1 20010628 WO 2000-FR3650 20001221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001028572 A5 20010703 AU 2001-28572 20001221  
 EP 1242365 A1 20020925 EP 2000-993510 20001221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003518086 T2 20030603 JP 2001-547037 20001221  
 US 2003203852 A1 20031030 US 2002-169053 20020828

PRIORITY APPLN. INFO.: WO 1999-IB2038 A 19991222  
 WO 2000-FR3650 W 20001221

OTHER SOURCE(S): MARPAT 135:77104


AB N-acyl pseudo peptides X(CH<sub>2</sub>)<sub>m</sub>CH(NHR<sub>1</sub>)(CH<sub>2</sub>)<sub>n</sub>CO-Y-(CH<sub>2</sub>)<sub>p</sub>CH(NHR<sub>2</sub>)(CH<sub>2</sub>)<sub>q</sub>Z [R<sub>1</sub>, R<sub>2</sub> = (un)substituted C<sub>2</sub>-C<sub>24</sub> acyl; m, n = 0-10; p, q = 1-10; X, Z = a neutral or charged acid group or (at least one) functionalized auxiliary spacer, preferably carboxy[(C<sub>1</sub>-C<sub>5</sub>)alkoxy], carboxy[(C<sub>1</sub>-C<sub>5</sub>)alkylthio], phosphono[(C<sub>1</sub>-C<sub>5</sub>)alkoxy], phosphono[(C<sub>1</sub>-C<sub>5</sub>)alkylthio], dihydroxyphosphoryloxy[(C<sub>1</sub>-C<sub>5</sub>)alkoxy], dihydroxyphosphoryloxy, hydroxysulfonyloxy, hydroxysulfonyl[(C<sub>1</sub>-C<sub>5</sub>)alkoxy], hydroxysulfonyl[(C<sub>1</sub>-C<sub>5</sub>)alkylthio], hydroxysulfonyloxy[(C<sub>1</sub>-C<sub>5</sub>)alkoxy], and hydroxysulfonyloxy[(C<sub>1</sub>-C<sub>5</sub>)alkylthio]; Y = O, NH] were prepared as immunomodulators. The compds. can further be grafted on an antigen to modulate immune response or also grafted on a pharmaceutical substance to improve its therapeutic activity or its targeting. Thus, 3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1,10-diol 1-dihydrogen phosphate 10-(6-oxohexanoate) was prepared and reacted to form conjugates with peptides (NANP)6P2P30, P2P30, and (NANP)3CS.T3 as well as ovalbumin and hemagglutinin H1N1. Compds. of the invention were evaluated pharmacol.

IT **346669-87-2P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of acyl pseudo peptides bearing a functionalized auxiliary spacer)

RN 346669-87-2 CAPLUS

CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 346669-86-1P 346669-94-1P 346670-02-8P  
 346670-10-8P 346670-11-9P 346670-13-1P  
 346670-14-2P 346670-15-3P 346670-18-6P  
 346670-19-7P 346670-20-0P 346670-22-2P  
 346670-25-5P 346670-26-6P 346670-27-7P  
 346670-28-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer)

RN 346669-86-1 CAPLUS


CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6,7-dihydroxy-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346669-94-1 CAPLUS

CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6-amino-1-oxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346670-02-8 CAPLUS

340370-02-9 (9CI) (CA INDEX  
 NAME)  
 Dodecanoic acid, (1R)-1-[2-[[[(1S)-1-[[[(4R)-5-[(6-hydroxy-1-oxohexyl)oxy]-  
 4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-  
 (phosphonoxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.




RN 346670-10-8 CAPLUS

540070-10-9 9CI  
 CN Dodecanoic acid, (1R)-1-[2-[[[(1R)-1-[(carboxymethoxy)methyl]-2-[[[(4R)-5-  
 [(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 346670-11-9 CAPLUS


CN Tetradecanoic acid, (1R)-1-[2-[[[(1S)-2-[[[(4R)-5-[(7-amino-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-1-[[[(carboxymethyl)thio]methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 346670-13-1 CAPLUS


CN Propanedioic acid, [[(2R)-3-[[[(4R)-5-[(1,6-dioxohexyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]-3-oxo-2-[[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]propoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346670-14-2 CAPLUS  
 CN Dodecanoic acid, (1R,11R)-22-bromo-11-[[ (3R)-3-hydroxy-1-oxotetradecyl]amino]-3,6,14,21-tetraoxo-5-[2-(phosphonooxy)ethyl]-1-undecyl-13-oxa-4,7,20-triazadocos-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346670-15-3 CAPLUS  
 CN Dodecanoic acid, (1R,5R)-5-[[ (1,6-dioxohexyl)oxy]methyl]-15,15-dihydroxy-11-[[ (3R)-3-hydroxy-1-oxotetradecyl]amino]-15-oxido-3,10-dioxo-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 346670-18-6 CAPLUS  
 CN Glycine, N-[(9R,19R)-9-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-6,14,17,21-tetraoxo-15-[2-(phosphonooxy)ethyl]-19-undecyl-7,20-dioxo-13,16-diazadotriacont-1-yl]-L-phenylalanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




RN 346670-19-7 CAPLUS  
 CN Dodecanoic acid, 1-[2-[[1-[[[5-[(1,6-dioxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)




RN 346670-20-0 CAPLUS

Odocoetoxic acid, 1-[2-[[1-[[[5-(6-amino-1-oxohexyl)oxy]-4-[(3-hydroxy-1-oxododecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)



RN 346670-22-2 CAPLUS

Dodecanoic acid, 1-[2-[[[1-[[[5-(6-hydroxy-1-oxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)




RN 346670-25-5 CAPLUS

CN Tetradecanoic acid, 1-[2-[[2-[[5-[(7-amino-1-oxoheptyl)oxy]-4-[(3-hydroxy-



1-oxotetradecyl)amino]pentyl]amino]-1-[[ (carboxymethyl)thio]methyl]-2-oxoethyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— (CH<sub>2</sub>)<sub>12</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me

RN 346670-26-6 CAPLUS

CN Propanedioic acid, [[3-[[5-[(1,6-dioxohexyl)oxy]-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]-3-oxo-2-[[1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]propoxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH<sub>2</sub>)<sub>10</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me


RN 346670-27-7 CAPLUS

CN Dodecanoic acid, 22-bromo-11-[(3-hydroxy-1-oxotetradecyl)amino]-3,6,14,21-tetraoxo-5-[2-(phosphonooxy)ethyl]-1-undecyl-13-oxa-4,7,20-triazadocos-1-yl ester (9CI) (CA INDEX NAME)



RN 346670-28-8 CAPLUS  
 CN Dodecanoic acid, 5-[[[(1,6-dioxohexyl)oxy]methyl]-15,15-dihydroxy-11-[(3-hydroxy-1-oxotetradecyl)amino]-15-oxido-3,10-dioxo-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— (CH<sub>2</sub>)<sub>10</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me

IT 253587-01-8P 346669-83-8P 346669-84-9P  
 346669-85-0P 346669-92-9P 346669-93-0P  
 346670-00-6P 346670-01-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of acyl pseudopeptides bearing a functionalized auxiliary spacer)

RN 253587-01-8 CAPLUS  
 CN Dodecanoic acid, (1R,11R,15R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-11-(hydroxymethyl)-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346669-83-8 CAPLUS


CN Dodecanoic acid, (1R,11R,15R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-3,6,13-trioxo-11-[[1-oxo-6-heptenyl]oxy]methyl]-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 346669-84-9 CAPLUS


CN Dodecanoic acid, (1R,11R,15R)-11-[[1-oxo-6-heptenyl]oxy]methyl]-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346669-85-0 CAPLUS  
 CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6,7-dihydroxy-1-oxoheptyl)oxy]-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-[(diphenoxyphosphinyl)oxy]propyl]amino]-2-oxoethyl]dodecyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 346669-92-9 CAPLUS  
 CN 9,22-Dioxa-2,15,18-triazatetratriacontanoic acid, 17-[2-  
 [(diphenoxyphosphinyl)oxy]ethyl]-8,16,19,23-tetraoxo-11-[[ (3R)-1-oxo-3-  
 (phenylmethoxy)tetradecyl]amino]-21-undecyl-, phenylmethyl ester,  
 (11R,21R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 346669-93-0 CAPLUS  
 CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-[(6-amino-1-oxohexyl)oxy]-4-  
 [[ (3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-

[(diphenoxyphosphinyl)oxy]propyl]amino]-2-oxoethyl]dodecyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 346670-00-6 CAPLUS

CN Dodecanoic acid, (1R, 5S, 11R, 15R)-5-(2-hydroxyethyl)-3,6,13-trioxo-17-phenyl-11-[[[(phenylmethoxy)methoxy]methyl]-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346670-01-7 CAPLUS

CN Dodecanoic acid, (1R, 5S, 11R, 15R)-5-[2-[[[bis(phenylmethoxy)phosphinyl]oxy]ethyl]-11-(hydroxymethyl)-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:15159 CAPLUS

DOCUMENT NUMBER: 132:73642

TITLE: Acyl pseudodipeptides, preparation method, pharmaceutical compositions containing them for therapeutic use

INVENTOR(S): Bauer, Jacques; Martin, Olivier Richard

PATENT ASSIGNEE(S): Om Pharma, Switz.

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000462	A1	20000106	WO 1999-IB1170	19990623
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337807	AA	20000106	CA 1999-2337807	19990623
AU 9942848	A1	20000117	AU 1999-42848	19990623
AU 761396	B2	20030605		
EP 1091928	A1	20010418	EP 1999-957636	19990623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9911329	A	20011016	BR 1999-11329	19990623
EE 200000791	A	20020215	EE 2000-791	19990623
JP 2002519338	T2	20020702	JP 2000-557223	19990623
PRIORITY APPLN. INFO.:				
			WO 1998-FR1396	A 19980630
			FR 1998-1396	A 19980630
			WO 1999-IB1170	W 19990623

OTHER SOURCE(S): MARPAT 132:73642


AB The invention discloses N-acyl pseudodipeptides  
 $\text{XA}(\text{CH}_2)_m\text{CH}(\text{NHR}_1)(\text{CH}_2)_n\text{CONH}(\text{CH}_2)_p\text{CH}(\text{NHR}_2)(\text{CH}_2)_q\text{BY}$  [ $\text{R}_1, \text{R}_2 = (\text{un})\text{saturated} (\text{un})\text{branched} (\text{un})\text{substituted C2-24 carboxylic acid}; m, p, q = 1-10; n = 0-10; \text{X, Y} = \text{H, phosphono, hydroxysulfonyl, dimethoxyphosphoryl, (C1-5 alkyl) carboxy, etc.}; \text{A, B} = \text{O, S, NH}$ ] and salts thereof. The invention also discloses pharmaceutical compns. containing as active principle at least one of the above compds. The compds. have interesting pharmacol. properties which make them useful as medicines especially as immunomodulators. The compds. are of interest in the treatment of immune deficiency diseases and diseases involving hyperimmune response, in the treatment of cancer, and as vaccine adjuvants. Their amphiphilic character makes them useful in drug delivery systems.

IT **253587-00-7P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (acyl pseudodipeptide preparation and pharmaceutical compns. for therapeutic use)

RN 253587-00-7 CAPLUS

CN Dodecanoic acid, (1R,11R)-14,14-dihydroxy-11-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-14-oxido-3,6-dioxo-5-[2-(phosphonooxy)ethyl]-1-undecyl-13-oxa-4,7-diaza-14-phosphatetradec-1-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **253586-86-6 253586-87-7 253586-88-8 253586-89-9 253586-90-2**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (acyl pseudodipeptide preparation and pharmaceutical compns. for therapeutic use)

RN 253586-86-6 CAPLUS

CN Dodecanoic acid, 1-[2-[[1-[[[5-hydroxy-4-[(3-hydroxy-1-oxotetradecyl)amino]pentyl]amino]carbonyl]-3-(phosphonooxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B


— (CH<sub>2</sub>)<sub>10</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me

RN 253586-87-7 CAPLUS

CN Dodecanoic acid, 14,14-dihydroxy-5-(2-hydroxyethyl)-11-[(3-hydroxy-1-oxotetradecyl)amino]-14-oxido-3,6-dioxo-1-undecyl-13-oxa-4,7-diaza-14-phosphatetradec-1-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— (CH<sub>2</sub>)<sub>10</sub>—Me

— (CH<sub>2</sub>)<sub>10</sub>—Me

RN 253586-88-8 CAPLUS

CN Dodecanoic acid, 14,14-dihydroxy-11-[(3-hydroxy-1-oxotetradecyl)amino]-14-oxido-3,6-dioxo-5-[2-(phosphonooxy)ethyl]-1-undecyl-13-oxa-4,7-diaza-14-phosphatetradec-1-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$$\text{---}(\text{CH}_2)_{10}\text{---Me}$$
$$-(\text{CH}_2)_{10}-\text{Me}$$

RN 253586-89-9 CAPLUS

CN Dodecanoic acid, (1R,5R)-15,15-dihydroxy-11-[[ (3R)-3-hydroxy-1-oxotetradecyl]amino]-15-oxido-3,10-dioxo-5-[(phosphonooxy)methyl]-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253586-90-2 CAPLUS

CN Dodecanoic acid, (1R,5R)-15,15-dihydroxy-5-(hydroxymethyl)-11-[[ (3R)-3-hydroxy-1-oxotetradecyl]amino]-15-oxido-3,10-dioxo-1-undecyl-14-oxa-4,9-diaza-15-phosphapentadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253586-98-0P 253586-99-1P 253587-02-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction; acyl pseudodipeptide preparation and pharmaceutical compns. for therapeutic use)

RN 253586-98-0 CAPLUS

CN Dodecanoic acid, (1R)-1-[2-[[1-[[[(4R)-5-hydroxy-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]-3-(phosphonoxy)propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253586-99-1 CAPLUS

CN Dodecanoic acid, (1R)-1-[2-[[3-[(diphenoxyphosphinyl)oxy]-1-[[[(4R)-5-hydroxy-4-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]pentyl]amino]carbonyl]propyl]amino]-2-oxoethyl]dodecyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253587-02-9 CAPLUS

CN Dodecanoic acid, (1R,11R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-14,14-dihydroxy-11-[[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-14-oxido-3,6-dioxo-1-undecyl-13-oxa-4,7-diaza-14-phosphatetradec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 253587-01-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction; acyl pseudodipeptide preparation and pharmaceutical compns. for therapeutic use)

RN 253587-01-8 CAPLUS

CN Dodecanoic acid, (1R,11R,15R)-5-[2-[(diphenoxyphosphinyl)oxy]ethyl]-11-(hydroxymethyl)-3,6,13-trioxo-17-phenyl-1,15-diundecyl-16-oxa-4,7,12-triazaheptadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b caold  
FILE 'CAOLD' ENTERED AT 08:58:29 ON 10 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d que nos l10  
L1 STR  
L2 SCR 1237  
L3 SCR 1236 AND 1297  
L4 SCR 1236 AND 1332  
L5 SCR 1235 AND 1298  
L6 SCR 1235 AND 1332  
L7 35 SEA FILE=REGISTRY SSS FUL L1 AND (L2 OR L3 OR L4 OR L5 OR L6)  
L10 0 SEA FILE=CAOLD ABB=ON PLU=ON L7

=> b home  
FILE 'HOME' ENTERED AT 08:58:47 ON 10 DEC 2003

=>